NCT04370236 Phase 2, phase 3 Terminated
INB03 for the Treatment of Pulmonary Complications From COVID-19 Study sponsor: Inmune Bio, Inc. · INMB
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2021-10-13 Actual
Enrollment · participants 79 Actual
Source updated 2026-05-19 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-11-25 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Proportion of Participants With Disease Progression From Randomization to 28 Days Post-randomization
+ After Measure: Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial